nanotech-investing Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
nanotech-investing Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
nanotech-investing Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
nanotech-investing Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome , a Rare Pediatric Congenital Heart Defect
nanotech-investing Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
nanotech-investing George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
nanotech-investing Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa
nanotech-investing Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
nanotech-investing Longeveron® Announces Contract Development and Manufacturing Business and First Contract
nanotech-investing Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
CORRECTION - Domestic Metals Engages ICP Securities Inc. for Automated Market Making Services and provides further details on the engagement of Michael Pound
